Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Loss of Blood-Brain Barrier Integrity in a KCl-Induced Model of Episodic Headache Enhances CNS Drug Delivery.

Cottier KE, Galloway EA, Calabrese EC, Tome ME, Liktor-Busa E, Kim J, Davis TP, Vanderah TW, Largent-Milnes TM.

eNeuro. 2018 Jul 16;5(4). pii: ENEURO.0116-18.2018. doi: 10.1523/ENEURO.0116-18.2018. eCollection 2018 Jul-Aug.

2.

Peripherally restricted cannabinoid 1 receptor agonist as a novel analgesic in cancer-induced bone pain.

Zhang H, Lund DM, Ciccone HA, Staatz WD, Ibrahim MM, Largent-Milnes TM, Seltzman HH, Spigelman I, Vanderah TW.

Pain. 2018 Sep;159(9):1814-1823. doi: 10.1097/j.pain.0000000000001278.

PMID:
29781960
3.

Continuous remote ischemic conditioning attenuates cognitive and motor deficits from moderate traumatic brain injury.

Pandit V, Khan M, Zakaria ER, Largent-Milnes TM, Hamidi M, O'Keeffe T, Vanderah TW, Joseph B.

J Trauma Acute Care Surg. 2018 Jul;85(1):48-53. doi: 10.1097/TA.0000000000001835.

PMID:
29443855
4.

17-β-Estradiol induces spreading depression and pain behavior in alert female rats.

Sandweiss AJ, Cottier KE, McIntosh MI, Dussor G, Davis TP, Vanderah TW, Largent-Milnes TM.

Oncotarget. 2017 Dec 9;8(69):114109-114122. doi: 10.18632/oncotarget.23141. eCollection 2017 Dec 26.

5.

A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain.

Edwards KA, Havelin JJ, Mcintosh MI, Ciccone HA, Pangilinan K, Imbert I, Largent-Milnes TM, King T, Vanderah TW, Streicher JM.

J Pain. 2018 Jun;19(6):612-625. doi: 10.1016/j.jpain.2018.01.002. Epub 2018 Jan 31.

PMID:
29371114
6.

Effect of Centruroides antivenom on reversal of methamphetamine-induced hyperkinesis and hyperthermia in rats.

Malekzadeh P, Hu J, Sandweiss AJ, Ameli N, Bierny P, Largent-Milnes TM, Vanderah TW, Shirazi F.

J Pharm Pharmacol (Los Angel). 2017 Apr;5(1). pii: 5. doi: 10.13188/2327-204X.1000020. Epub 2017 Apr 20.

7.

Dissecting the role of the CRMP2-neurofibromin complex on pain behaviors.

Moutal A, Wang Y, Yang X, Ji Y, Luo S, Dorame A, Bellampalli SS, Chew LA, Cai S, Dustrude ET, Keener JE, Marty MT, Vanderah TW, Khanna R.

Pain. 2017 Nov;158(11):2203-2221. doi: 10.1097/j.pain.0000000000001026.

PMID:
28767512
8.

Remote ischemic conditioning preserves cognition and motor coordination in a mouse model of traumatic brain injury.

Sandweiss AJ, Azim A, Ibraheem K, Largent-Milnes TM, Rhee P, Vanderah TW, Joseph B.

J Trauma Acute Care Surg. 2017 Dec;83(6):1074-1081. doi: 10.1097/TA.0000000000001626.

PMID:
28609381
9.

Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation.

Grenald SA, Doyle TM, Zhang H, Slosky LM, Chen Z, Largent-Milnes TM, Spiegel S, Vanderah TW, Salvemini D.

Pain. 2017 Sep;158(9):1733-1742. doi: 10.1097/j.pain.0000000000000965.

10.

Blocking CRMP2 SUMOylation reverses neuropathic pain.

Moutal A, Dustrude ET, Largent-Milnes TM, Vanderah TW, Khanna M, Khanna R.

Mol Psychiatry. 2017 May 23. doi: 10.1038/mp.2017.117. [Epub ahead of print] No abstract available.

PMID:
28533518
11.

Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.

Sandweiss AJ, McIntosh MI, Moutal A, Davidson-Knapp R, Hu J, Giri AK, Yamamoto T, Hruby VJ, Khanna R, Largent-Milnes TM, Vanderah TW.

Mol Psychiatry. 2017 May 9. doi: 10.1038/mp.2017.102. [Epub ahead of print]

12.

Homology-guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2-derived peptides.

Moutal A, Li W, Wang Y, Ju W, Luo S, Cai S, François-Moutal L, Perez-Miller S, Hu J, Dustrude ET, Vanderah TW, Gokhale V, Khanna M, Khanna R.

Br J Pharmacol. 2018 Jun;175(12):2244-2260. doi: 10.1111/bph.13737. Epub 2017 Mar 17.

PMID:
28161890
13.

Long-lasting antinociceptive effects of green light in acute and chronic pain in rats.

Ibrahim MM, Patwardhan A, Gilbraith KB, Moutal A, Yang X, Chew LA, Largent-Milnes T, Malan TP, Vanderah TW, Porreca F, Khanna R.

Pain. 2017 Feb;158(2):347-360. doi: 10.1097/j.pain.0000000000000767.

14.

Cognitive impairment in heart failure: A protective role for angiotensin-(1-7).

Hay M, Vanderah TW, Samareh-Jahani F, Constantopoulos E, Uprety AR, Barnes CA, Konhilas J.

Behav Neurosci. 2017 Feb;131(1):99-114. doi: 10.1037/bne0000182. Epub 2017 Jan 5.

PMID:
28054808
15.

Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists.

Grenald SA, Young MA, Wang Y, Ossipov MH, Ibrahim MM, Largent-Milnes TM, Vanderah TW.

Neuropharmacology. 2017 Apr;116:59-70. doi: 10.1016/j.neuropharm.2016.12.008. Epub 2016 Dec 20.

16.

Structure-Activity Relationships of [des-Arg7]Dynorphin A Analogues at the κ Opioid Receptor.

Ramos-Colon CN, Lee YS, Remesic M, Hall SM, LaVigne J, Davis P, Sandweiss AJ, McIntosh MI, Hanson J, Largent-Milnes TM, Vanderah TW, Streicher J, Porreca F, Hruby VJ.

J Med Chem. 2016 Nov 23;59(22):10291-10298. Epub 2016 Nov 8.

17.

The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain.

Slosky LM, BassiriRad NM, Symons AM, Thompson M, Doyle T, Forte BL, Staatz WD, Bui L, Neumann WL, Mantyh PW, Salvemini D, Largent-Milnes TM, Vanderah TW.

Pain. 2016 Nov;157(11):2605-2616.

18.

A new paradigm for pain?

Davis B, Vanderah TW.

J Fam Pract. 2016 Sep;65(9):598-605. Review.

PMID:
27672685
19.

Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain.

Forte BL, Slosky LM, Zhang H, Arnold MR, Staatz WD, Hay M, Largent-Milnes TM, Vanderah TW.

Pain. 2016 Dec;157(12):2709-2721.

20.

Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential.

Xie JY, Chew LA, Yang X, Wang Y, Qu C, Wang Y, Federici LM, Fitz SD, Ripsch MS, Due MR, Moutal A, Khanna M, White FA, Vanderah TW, Johnson PL, Porreca F, Khanna R.

Pain. 2016 Sep;157(9):2124-40. doi: 10.1097/j.pain.0000000000000628.

21.

Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent.

Hanlon KE, Lozano-Ondoua AN, Umaretiya PJ, Symons-Liguori AM, Chandramouli A, Moy JK, Kwass WK, Mantyh PW, Nelson MA, Vanderah TW.

Breast Cancer (Dove Med Press). 2016 Apr 15;8:59-71. doi: 10.2147/BCTT.S100393. eCollection 2016.

22.

(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology.

Moutal A, Chew LA, Yang X, Wang Y, Yeon SK, Telemi E, Meroueh S, Park KD, Shrinivasan R, Gilbraith KB, Qu C, Xie JY, Patwardhan A, Vanderah TW, Khanna M, Porreca F, Khanna R.

Pain. 2016 Jul;157(7):1448-63. doi: 10.1097/j.pain.0000000000000555.

23.

Design synthesis and structure-activity relationship of 5-substituted (tetrahydronaphthalen-2yl)methyl with N-phenyl-N-(piperidin-2-yl)propionamide derivatives as opioid ligands.

Deekonda S, Rankin D, Davis P, Lai J, Vanderah TW, Porecca F, Hruby VJ.

Bioorg Med Chem. 2016 Jan 15;24(2):85-91. doi: 10.1016/j.bmc.2015.11.030. Epub 2015 Nov 23.

24.

Enkephalin analogues with N-phenyl-N-(piperidin-2-ylmethyl)propionamide derivatives: Synthesis and biological evaluations.

Deekonda S, Cole J, Sunna S, Rankin D, Largent-Milnes TM, Davis P, BassiriRad NM, Lai J, Vanderah TW, Porecca F, Hruby VJ.

Bioorg Med Chem Lett. 2016 Jan 1;26(1):222-7. doi: 10.1016/j.bmcl.2015.10.081. Epub 2015 Nov 3.

25.

Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.

Giri AK, Apostol CR, Wang Y, Forte BL, Largent-Milnes TM, Davis P, Rankin D, Molnar G, Olson KM, Porreca F, Vanderah TW, Hruby VJ.

J Med Chem. 2015 Nov 12;58(21):8573-83. doi: 10.1021/acs.jmedchem.5b01170. Epub 2015 Oct 30.

26.

The pharmacology of neurokinin receptors in addiction: prospects for therapy.

Sandweiss AJ, Vanderah TW.

Subst Abuse Rehabil. 2015 Sep 7;6:93-102. doi: 10.2147/SAR.S70350. eCollection 2015. Review.

27.

Use of Animal Models in Understanding Cancer-induced Bone Pain.

Slosky LM, Largent-Milnes TM, Vanderah TW.

Cancer Growth Metastasis. 2015 Aug 23;8(Suppl 1):47-62. doi: 10.4137/CGM.S21215. eCollection 2015. Review.

28.

Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives.

Deekonda S, Wugalter L, Rankin D, Largent-Milnes TM, Davis P, Wang Y, Bassirirad NM, Lai J, Kulkarni V, Vanderah TW, Porreca F, Hruby VJ.

Bioorg Med Chem Lett. 2015 Oct 15;25(20):4683-8. doi: 10.1016/j.bmcl.2015.07.064. Epub 2015 Jul 29.

29.

Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands.

Deekonda S, Wugalter L, Kulkarni V, Rankin D, Largent-Milnes TM, Davis P, Bassirirad NM, Lai J, Vanderah TW, Porreca F, Hruby VJ.

Bioorg Med Chem. 2015 Sep 15;23(18):6185-94. doi: 10.1016/j.bmc.2015.07.071. Epub 2015 Aug 4.

30.

Blockade of non-opioid excitatory effects of spinal dynorphin A at bradykinin receptors.

Lee YS, Hall SM, Ramos-Colon C, Remesic M, Rankin D, Vanderah TW, Porreca F, Lai J, Hruby VJ.

Receptors Clin Investig. 2015;2(1). pii: 517.

31.

Discovery of tripeptide-derived multifunctional ligands possessing delta/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities.

Nair P, Yamamoto T, Cowell S, Kulkarni V, Moye S, Navratilova E, Davis P, Ma SW, Vanderah TW, Lai J, Porreca F, Hruby VJ.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3716-20. doi: 10.1016/j.bmcl.2015.06.030. Epub 2015 Jun 15.

32.

Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain.

Ford A, Castonguay A, Cottet M, Little JW, Chen Z, Symons-Liguori AM, Doyle T, Egan TM, Vanderah TW, De Koninck Y, Tosh DK, Jacobson KA, Salvemini D.

J Neurosci. 2015 Apr 15;35(15):6057-67. doi: 10.1523/JNEUROSCI.4495-14.2015. Erratum in: J Neurosci. 2015 Jun 10;35(23):8971.

33.

A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors.

François-Moutal L, Wang Y, Moutal A, Cottier KE, Melemedjian OK, Yang X, Wang Y, Ju W, Largent-Milnes TM, Khanna M, Vanderah TW, Khanna R.

Pain. 2015 Jul;156(7):1247-64. doi: 10.1097/j.pain.0000000000000147.

34.

Therapeutic potential of peroxynitrite decomposition catalysts: a patent review.

Slosky LM, Vanderah TW.

Expert Opin Ther Pat. 2015 Apr;25(4):443-66. doi: 10.1517/13543776.2014.1000862. Epub 2015 Jan 9. Review.

PMID:
25576197
35.

Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis.

Dzierlenga AL, Clarke JD, Hargraves TL, Ainslie GR, Vanderah TW, Paine MF, Cherrington NJ.

J Pharmacol Exp Ther. 2015 Mar;352(3):462-70. doi: 10.1124/jpet.114.220764. Epub 2014 Dec 15.

36.

Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states.

Little JW, Ford A, Symons-Liguori AM, Chen Z, Janes K, Doyle T, Xie J, Luongo L, Tosh DK, Maione S, Bannister K, Dickenson AH, Vanderah TW, Porreca F, Jacobson KA, Salvemini D.

Brain. 2015 Jan;138(Pt 1):28-35. doi: 10.1093/brain/awu330. Epub 2014 Nov 19.

37.

Animal models for opioid addiction drug discovery.

Grenald SA, Largent-Milnes TM, Vanderah TW.

Expert Opin Drug Discov. 2014 Nov;9(11):1345-54. doi: 10.1517/17460441.2014.966076. Epub 2014 Oct 13. Review.

PMID:
25307021
38.

Discovery of amphipathic dynorphin A analogues to inhibit the neuroexcitatory effects of dynorphin A through bradykinin receptors in the spinal cord.

Lee YS, Muthu D, Hall SM, Ramos-Colon C, Rankin D, Hu J, Sandweiss AJ, De Felice M, Xie JY, Vanderah TW, Porreca F, Lai J, Hruby VJ.

J Am Chem Soc. 2014 May 7;136(18):6608-16. doi: 10.1021/ja501677q. Epub 2014 Apr 29.

39.

Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain.

Podolsky AT, Sandweiss A, Hu J, Bilsky EJ, Cain JP, Kumirov VK, Lee YS, Hruby VJ, Vardanyan RS, Vanderah TW.

Life Sci. 2013 Dec 18;93(25-26):1010-6. doi: 10.1016/j.lfs.2013.09.016. Epub 2013 Sep 29.

40.

Cancer-induced bone pain: Mechanisms and models.

Lozano-Ondoua AN, Symons-Liguori AM, Vanderah TW.

Neurosci Lett. 2013 Dec 17;557 Pt A:52-9. doi: 10.1016/j.neulet.2013.08.003. Epub 2013 Sep 25. Review.

41.

Acetaminophen modulates P-glycoprotein functional expression at the blood-brain barrier by a constitutive androstane receptor-dependent mechanism.

Slosky LM, Thompson BJ, Sanchez-Covarrubias L, Zhang Y, Laracuente ML, Vanderah TW, Ronaldson PT, Davis TP.

Mol Pharmacol. 2013 Nov;84(5):774-86. doi: 10.1124/mol.113.086298. Epub 2013 Sep 9.

42.

Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities.

Nair P, Yamamoto T, Largent-Milnes TM, Cowell S, Kulkarni V, Moye S, Navratilova E, Davis P, Ma SW, Vanderah TW, Lai J, Porreca F, Hruby VJ.

Bioorg Med Chem Lett. 2013 Sep 1;23(17):4975-8. doi: 10.1016/j.bmcl.2013.06.065. Epub 2013 Jul 2.

43.

Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects.

Largent-Milnes TM, Brookshire SW, Skinner DP Jr, Hanlon KE, Giuvelis D, Yamamoto T, Davis P, Campos CR, Nair P, Deekonda S, Bilsky EJ, Porreca F, Hruby VJ, Vanderah TW.

J Pharmacol Exp Ther. 2013 Oct;347(1):7-19. doi: 10.1124/jpet.113.205245. Epub 2013 Jul 16.

44.

Effect of anchoring 4-anilidopiperidines to opioid peptides.

Petrov RR, Lee YS, Vardanyan RS, Liu L, Ma SW, Davis P, Lai J, Porreca F, Vanderah TW, Hruby VJ.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3434-7. doi: 10.1016/j.bmcl.2013.03.065. Epub 2013 Apr 3.

45.

Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists.

Lozano-Ondoua AN, Hanlon KE, Symons-Liguori AM, Largent-Milnes TM, Havelin JJ, Ferland HL 3rd, Chandramouli A, Owusu-Ankomah M, Nikolich-Zugich T, Bloom AP, Jimenez-Andrade JM, King T, Porreca F, Nelson MA, Mantyh PW, Vanderah TW.

J Bone Miner Res. 2013 Jan;28(1):92-107. doi: 10.1002/jbmr.1732.

46.

Activation of TRPA1 on dural afferents: a potential mechanism of headache pain.

Edelmayer RM, Le LN, Yan J, Wei X, Nassini R, Materazzi S, Preti D, Appendino G, Geppetti P, Dodick DW, Vanderah TW, Porreca F, Dussor G.

Pain. 2012 Sep;153(9):1949-58. doi: 10.1016/j.pain.2012.06.012. Epub 2012 Jul 17.

47.

Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation.

Tumati S, Largent-Milnes TM, Keresztes AI, Yamamoto T, Vanderah TW, Roeske WR, Hruby VJ, Varga EV.

Eur J Pharmacol. 2012 Jun 5;684(1-3):64-70.

48.

Mechanisms of Bv8-induced biphasic hyperalgesia: increased excitatory transmitter release and expression.

De Felice M, Melchiorri P, Ossipov MH, Vanderah TW, Porreca F, Negri L.

Neurosci Lett. 2012 Jul 11;521(1):40-5. doi: 10.1016/j.neulet.2012.05.055. Epub 2012 May 26.

49.

Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors.

Pajouhesh H, Feng ZP, Zhang L, Pajouhesh H, Jiang X, Hendricson A, Dong H, Tringham E, Ding Y, Vanderah TW, Porreca F, Belardetti F, Zamponi GW, Mitscher LA, Snutch TP.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):4153-8. doi: 10.1016/j.bmcl.2012.04.054. Epub 2012 Apr 19.

50.

Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.

Tumati S, Largent-Milnes TM, Keresztes A, Ren J, Roeske WR, Vanderah TW, Varga EV.

J Neuroimmunol. 2012 Mar;244(1-2):23-31. doi: 10.1016/j.jneuroim.2011.12.021. Epub 2012 Jan 30.

Supplemental Content

Loading ...
Support Center